

Review

Open Access

## Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma

Liviu Feller\* and Johan Lemmer

Address: Department of Periodontology and Oral Medicine, Box D26 School of Dentistry, University of Limpopo Medunsa Campus, Pretoria, South Africa

Email: Liviu Feller\* - lfeller@medunsa.ac.za; Johan Lemmer - perio@medunsa.ac.za

\* Corresponding author

Published: 21 January 2008

Received: 7 November 2007

*Infectious Agents and Cancer* 2008, **3**:1 doi:10.1186/1750-9378-3-1

Accepted: 21 January 2008

This article is available from: <http://www.infectagentscancer.com/content/3/1/1>

© 2008 Feller and Lemmer; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

A decrease in the incidence of human immune deficiency virus-associated Kaposi sarcoma (HIV-KS) and regression of some established HIV-KS lesions is evident after the introduction of highly active anti-retroviral treatment (HAART), and is attributed to generalized immune restoration, to the reconstitution of human herpesvirus (HHV)-8 specific cellular immune responses, and to the decrease in HIV Tat protein and HHV-8 loads following HAART. However, a small subset of HIV-seropositive subjects with a low CD4+ T cell count at the time of introduction of HAART, may develop HIV-KS as immune reconstitution inflammatory syndrome (IRIS) within 8 weeks thereafter.

### Introduction

Kaposi sarcoma (KS) is the most common human immunodeficiency virus (HIV)-associated neoplasm [1]. HIV-associated Kaposi sarcoma (HIV-KS) lesions are characterized microscopically by angiogenesis, the presence of spindle-shaped tumour cells, inflammatory cell infiltrates dominated by mononuclear cells, extravasated erythrocytes and oedema [2-4]. Clinically, HIV-seropositive subjects with KS exhibit mainly multifocal mucocutaneous patches, plaques and nodules, and less frequently organ involvement [5-7]. The most common site of extra-mucocutaneous HIV-KS involvement is the lymph nodes followed by the gastro-intestinal tract and the lungs. The oral cavity is commonly affected and is the initial site of involvement with KS in about 20% of HIV-seropositive subjects with KS [8]. Oedema is a major clinical feature associated with advanced KS. It results most frequently when a local inflammatory reaction induced by production of cytokines by KS cells is complicated either by lymphatic obstruction by the enlarging tumour itself, or less

commonly by proximal lymph node involvement [9]. The pathogenesis of HIV-KS is complex, and involves interaction between human herpesvirus (HHV)-8, HIV, inflammatory cytokines, and angiogenic factors in the presence of profound immune suppression [10-12]. However, the understanding of how these multiple factors interplay to initiate KS is incomplete [3].

HHV-8 is present in all four epidemiological forms of KS (classic, endemic, iatrogenic and HIV-KS). Seroprevalence studies demonstrate that HHV-8 DNA in peripheral blood mononuclear cells (PBMC) and specific antibodies to HHV-8 are associated with increased risk of KS, and there is a positive correlation between the HHV-8 viral load and the severity of KS. These lines of evidence indicate that HHV-8 is necessary for the development of KS, but since HHV-8 seroconversion in the general population is not uncommon and is much more common in HIV-seropositive subjects, but yet only some members of these popula-

tions develop KS, other co-factors are clearly necessary for the development of KS [13-29].

HIV contributes to the pathogenesis of KS through several mechanisms: HIV Tat protein directly promotes HHV-8 replication [30,31]; HIV induces the production of inflammatory cytokines [12,32], and causes a profound immune impairment that is conducive to the development of KS. The incidence and aggressiveness of KS is substantially increased in HIV-seropositive subjects compared to HIV-seronegative subjects [10,31,32]. This emphasizes the important role of HIV in the natural course of HIV-KS.

The use of highly active antiretroviral therapy (HAART) has resulted in a dramatic reduction in the morbidity and mortality in HIV-seropositive subjects [33-36]. HAART, although not directly affecting HHV-8 replication, indirectly brings about a decrease in HHV-8 viral load [37], a substantial reduction in the prevalence and incidence of HIV-KS [38-42], and improvement in the clinical manifestation of KS [43-52].

However, HAART does not ensure that KS will not develop, and in subjects receiving HAART, KS remains the most frequent HIV-associated neoplasm [5,53]. HIV-seropositive subjects who had already received HAART at the time of KS diagnosis, usually have less aggressive KS disease compared to HIV-seropositive subjects who were HAART naïve at the time of KS diagnosis [5,54]. In addition, KS sometimes recrudesces as an immune reconstitution inflammatory syndrome (IRIS) in HIV-seropositive subjects shortly after the introduction of HAART, despite an improvement in the CD4+ T cell count and controlled HIV viremia [55-60].

### **The natural course of HIV-KS**

There is a compelling body of information that supports the concept that HIV-KS is an opportunistic tumour that starts as a reactive hyperplasia and eventually may progress to a true neoplasia [12,13,16,23,60-64].

HIV-KS has its origin in an environment induced by inflammatory T helper (Th)-1 cytokines associated with a marked impairment of cellular immune responses, brought about by HIV infection. The inflammatory infiltrate in HIV-KS lesions comprise CD8+ T cells, monocytes, macrophages and dendritic cells. These cells produce inflammatory cytokines that together with HHV-8 gene products, activate endothelial cells and trigger the development of HIV-KS. Early HIV-KS lesions manifest clinically as indolent red-purple macules or papules, that show proliferation of endothelial cells and formation of slit-shaped vascular channels resembling well vascularized exuberant granulation tissue. In time, HIV-KS lesions

become nodular and may have an aggressive clinical behaviour [60,61].

The late-stage maculo-papular HIV-KS lesions are characterized by proliferation of spindle cells, of lymphatic and/or blood vascular endothelial origin. The spindle cells become the predominant cell type, though the vascular element is always evident [23,65,66]. The progression of HIV-KS is attributed to dysregulation in cell cycle growth and resistance to apoptotic signals mediated by altered cytokine networks, latent and dysregulated lytic HHV-8 genes and HIV Tat protein [3,67].

Early-stage HIV-KS is a polyclonal reactive angioproliferative disorder. This is evident from the multifocal characteristic of the HIV-KS lesions in the absence of metastasis; by the occasional regression of HIV-KS lesions either spontaneously or following the introduction of HAART; and by the lack of clonality [68]. In contrast, late stage HIV-KS lesions from disparate subjects may show a spectrum of multiclonal origin, monoclonality, oligoclonality and polyclonality, and it is likely that a subset of late-stage lesional cells of monoclonal origin undergo malignant transformation [69,70].

Most of HIV-KS spindle cells express HHV-8 latent genes, but not genes that are involved in lytic reactivation and replication of latently infected cells. However, some of the virally infected KS cells express HHV-8 lytic genes, that provide paracrine angioproliferative inductive signals to neighbouring endothelial and spindle cells mediating angiogenesis and spindle cell proliferation [23].

The persistent endothelial and spindle cell proliferation, in response to HHV-8 induced inflammatory and growth factors, and to HHV-8 oncogenes leads to dysregulated cell proliferation and survival, followed by cellular transformation and eventual progression to a monoclonal tumour [12,13,23]. The malignant transformation of HIV-KS cells, when and if it occurs, is probably driven by HHV-8 latent oncogenes and by the dysregulated constitutive activity of viral G protein-coupled receptor (vGPCR) expressed outside the lytic phase of the virus replication cycle, without notable cellular genetic and epigenetic mutation of cell cycle genes and/or tumour suppressor genes [3,62].

### **The implication of inflammatory cytokines in the pathogenesis of HIV-KS**

The pathogenesis of HIV-KS is related to infection with HHV-8 and HIV, and to persistent inflammation in the presence of high level of Th1-type inflammatory cytokines including tumour necrosis factor (TNF)- $\alpha$ , interferon (INF)- $\gamma$ , interleukin (IL)-1 $\beta$ , and IL-6, within an environment of immunosuppression. Increased HIV and HHV-8

loads and concurrent opportunistic infections only serve to perpetuate the inflammatory state [60,71]. It is probable that the increased level of inflammatory and angiogenic cytokines in all epidemiological forms of KS is the consequence of the local host immune activation against HHV-8 and the HHV-8 release of cytokines in response to the output of the HHV-8 genes [11,13].

High levels of inflammatory cytokines in early KS lesions trigger endothelial cells to express activation markers including vascular cell adhesion molecules, matrix metalloproteinase (MMP),  $\alpha_5\beta_1$  and  $\alpha V\beta_3$  integrins, growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inflammatory and angiogenic cytokines acting in both paracrine and autocrine manner. These activated endothelial cells acquire abnormal phenotypic and functional features (angiogenic phenotype) that may initiate and promote the development of HIV-KS [61].

Inflammatory cytokines have the capacity to reactivate latent HHV-8, resulting in an increase of HHV-8 plasma load and spread of HHV-8 in tissues, and to promote HIV replication, leading to a further production of HIV Tat protein and deterioration in host immune responses. Thus, inflammatory cytokines have the potential to perpetuate an environment conducive to HIV-KS initiation and progression [61].

#### $\alpha_5\beta_1$ and $\alpha V\beta_3$ integrins

The interactions between cells and extracellular matrix molecules (ECM) are mediated by cell membrane receptors belonging to the integrin family, that mediate cellular migration and growth [72,73]. The increased levels of inflammatory cytokines and bFGF found in HIV-KS lesions upregulate the expression of  $\alpha_5\beta_1$  and  $\alpha V\beta_3$  integrins on HIV-KS cells [74].

In HIV-seropositive subjects, extracellular HIV Tat protein binds to  $\alpha_5\beta_1$  and  $\alpha V\beta_3$  integrin receptors on KS endothelial and spindle cells, to provide them with the necessary signals for adhesion that is required for their subsequent proliferation in response to mitogenic stimuli by bFGF. HIV Tat protein also induces the synthesis of MMP-2 and MMP-9. The increased expression of MMPs in HIV-KS cells may lead to degradation of extracellular matrix components, facilitating the locomotion of endothelial cells and invasion of spindle cells [61,74,75].

In HIV-seronegative subjects with KS, cellular growth and migration, and the expression of MMPs are induced by ( $\alpha_5\beta_1$ )-fibronectin and ( $\alpha V\beta_3$ )-vitronectin interactions in the presence of bFGF. The presence of HIV Tat protein in HIV-KS fortifies the  $\alpha_5\beta_1$  and  $\alpha V\beta_3$  stimulation [76,77]. This might explain the increased frequency of KS and the

greater aggressiveness in clinical behaviour of HIV-KS compared to other epidemiological forms of KS.

#### The role of bFGF and VEGF in the pathogenesis of HIV-KS

VEGF and bFGF are angiogenic growth factors that are powerfully expressed in HIV-KS lesions and promote angiogenesis. Both induce MMPs production by endothelial cells, and vascular permeability and subsequently oedema that is an important feature of HIV-KS [74,78]. bFGF is produced by immunoregulatory cells, that are present in HIV-KS lesions, and by activated endothelial cells [79,80]. bFGF has an instrumental role in the development of HIV-KS. It can initiate and sustain neovascularization by providing mitogenic signals to activated endothelial cells and spindle cells [32,60,81]. This concept is supported by reports that the expression of bFGF is upregulated in HIV-KS spindle cells, and antibodies to bFGF mRNA substantially reduce the angiogenic and proliferative potential of HIV-KS cells [71]. In HIV-seropositive subjects with KS, bFGF mediates Tat-induced endothelial cell proliferation, and acts with HIV Tat in promoting the production of MMPs by endothelial cells [72,82].

VEGF is a potent specific endothelial cell mitogen produced by HIV-KS endothelial and spindle cells in response to inflammatory cytokines that induce angiogenesis through autocrine mechanisms [23,83]. VEGF can synergise with bFGF to induce vascular permeability and oedema, and angiogenesis [13,23], and it is expressed and upregulated by several HHV-8 proteins including vIL-6 and vGPCR and plays a significant part in the development of KS [65].

#### MMPs

MMPs are a family of proteolytic enzymes involved in degradation of extracellular matrix and basement membrane components. MMP gene expression is induced by a variety of stimuli including inflammatory cytokines, ECM-integrin interaction, growth factors, HIV Tat protein and HHV-8 proteins [13,65,75]. MMP-2 is upregulated in HIV-KS lesions and it may play a rôle in inducing vascular permeability and oedema and in promoting endothelial cell growth, angiogenesis and tumour invasion [74,84,85].

#### Oxidative and nitrative metabolites in the pathogenesis of HIV-KS

Persistent inflammatory state is conducive to the production of ongoing reactive oxidative and nitrative metabolites which are associated with tumourgenesis. They promote cell proliferation, initiate nuclear and mitochondrial DNA mutations, induce a proangiogenic environment, and inactivate DNA repair enzymes [71,86].

HIV-seropositive subjects have high tissue levels of reactive oxidative and nitrative metabolites owing to increased levels of proinflammatory cytokines, more frequent opportunistic infections and a reduction in the activity of antioxidant enzymes [87]. HIV-KS lesional cells express endogenous oxidative and nitrative metabolites which together with increased exogenous oxidative and nitrative metabolite levels, associated with HIV infection, may promote the particular aggressiveness of KS in HIV-seropositive subjects [71].

### **HIV infection, HAART and KS**

HIV infection may directly and indirectly promote the initiation and progression of KS. HIV Tat protein, a transcriptional activator of HIV gene expression, is a major factor implicated in the pathogenesis of HIV-KS [82]. Tat protein is released by HIV-infected T cells. In this extracellular form, Tat synergises with inflammatory cytokines, which are upregulated in HIV-KS lesions, to promote angiogenesis, and progression of HIV-KS. It does this by the induction and mobilization of bFGF, and by interacting with  $\alpha_5\beta_1$  and  $\alpha V\beta_3$  integrins on both endothelial and spindle cells [75,80]. The coordinated signalling to endothelial cells integrins  $\alpha_5\beta_1$  and  $\alpha V\beta_3$  and growth factor receptors by Tat protein and bFGF respectively, are important events in the pathogenesis of HIV-KS [12,76].

By binding to  $\alpha_5\beta_1$  and  $\alpha V\beta_3$  integrins on inflammatory cytokine-activated endothelial cells, Tat protein activates the cascade of events in the FAS-ERK-MAPK intracellular signal transduction pathway. This promotes the progression of KS endothelial cells through the G1 cell cycle phase in response to bFGF stimulation, and results in increased cell proliferation [76]. In addition, Tat protein may act as an antiapoptotic agent causing prolonged survival of endothelial cells [67]. It also has the capacity to regulate the cycle of HHV-8 growth and to reactivate latent HHV-8 infection [9,13]. A further outcome of the activity of Tat protein can be an increase in the synthesis of MMP-2 by monocytes and by endothelial cells leading to increased vascular permeability and oedema [74].

HIV infection may indirectly affect the course of HIV-KS by perpetuating immunosuppression and immunodysregulation, characterized by increased production of proinflammatory cytokines that sustain the KS [13]. Moreover, Tat protein induces in monocyte-derived dendritic cells an increase in production of Th1 type cytokines and  $\beta$  chemokines [77].

Following the introduction of HAART sometimes established HIV-KS may regress and the likelihood of developing new lesions of KS is diminished [5,9,13,38,40]. This can be attributed to three factors. Firstly, the reduction in HIV load, Tat protein and inflammatory cytokines [13],

secondly, HHV-8 specific – CD8 + cytotoxic T lymphocyte response is improved following HAART [13,88,89] and therefore there is a reduction in HHV-8 load. Thirdly, some protease inhibitors that are administered as a component of HAART have anti-inflammatory and anti-angiogenic activity, thus directly inhibiting HIV-KS [10].

However, despite otherwise effective HAART, established HIV-KS may not always regress, and new KS lesions may appear [13,54], perhaps as a manifestation of immune reconstitution inflammatory syndrome (IRIS) [30,33,55,56,59].

### **HIV associated IRIS**

IRIS can be defined as an exuberant immune-mediated inflammatory response to a pre-existing subclinical pathogen or tumour antigen after treatment has brought about an improvement in a host previously profoundly depressed immunity [55,59,90]. In the context of HIV infection, HAART-induced IRIS has been described in relation to opportunistic infections including herpes simplex (HS), herpes zoster (HZ), mycobacterium tuberculosis, in relation to autoimmune thyroid disease, and in relation to KS. HIV-IRIS occurs paradoxically despite a reduction in HIV load and improvement in all HIV related immunologic parameters early after the introduction of HAART, and is probably the result of reconstituted pathogen-specific immune responses [33,89,91-96]. However, the details regarding the immunopathogenic mechanisms that bring about IRIS are speculative [96].

In HIV-seropositive subjects who start HAART at an early stage of HIV infection, the number and function of CD4+ T cells tend to return to normal. On the other hand, subjects who start HAART, when the HIV infection is moderately advanced (CD4+ T cell counts are between  $100 \times 10^6/L$  and  $300 \times 10^6/L$ ), will not show a similar recovery. However, even such a partial immune reconstitution results in a profound decline in HIV-associated morbidity and mortality [97].

CD4+ T cell restoration in peripheral blood after HAART is biphasic. An initial rapid increase during the first 12 weeks of treatment is followed by a more gradual increase over the remainder of the first year, and after that there is usually no further significant improvement. The initial-phase increase in the CD4+ T cells is due to proliferation and reduced apoptosis of existing memory cells in the circulation and to redistribution of CD4+ T cells from the lymph nodes into the circulation. Only after several months of HAART, will T lymphoiesis associated with improvement of thymic function become evident, giving rise to increased numbers of naïve T lymphocytes [89,97-105]. With continued HAART there will also be an increase in CD8+ T cells in the circulation lagging behind

the peak increase in CD4+ T cells by a period of about 5 weeks. During the initial immune reconstitution phase the ability of the host to mount immuno-inflammatory responses is restored [33,106], owing to the partial recovery of CD4+ T cells and CD8+ cytotoxic T cell responses, and the shift from a Th-2- to a Th-1-dominant cytokine profile.

All HIV-IRIS events occur in subjects who display as indicators of immune reconstitution, a decrease in HIV viral load and an increase in CD4+ T cell count. HIV-seropositive subjects with IRIS episodes tend to be younger at the time of introduction of HAART and tend to have a lower median baseline CD4+ T cell percentage than HIV-seropositive subjects who do not experience IRIS. Overall, the median time to onset of IRIS in those subjects who display this response is 12 weeks [92-96].

HIV-seropositive subjects who are at greater risk for developing IRIS are those with low CD4+ T cell counts of < 100 cells/ul [95,107], those with CD4+ T cell percentage of <10%, and those of a younger age at the time of introduction of HAART [96]. There is no association between the risk for developing IRIS and the magnitude of the increase in CD4+ T cell count or the percentage of CD4+ T cell increase, and the plasma load decrease following HAART [95,96,108]. In contrast, Shelburne et al.[94] and Breton et al.[109] found that HIV-IRIS is associated with a greater increase in the percentage of CD4+ T cell one month after the introduction of HAART and with a more pronounced and persistent reduction in HIV load. Thus, there is some conflict in the immunological parameters associated with the development of HIV-IRIS.

The definite association of the events of HIV-IRIS with a low baseline CD4+ T cell percentage probably reflects a higher burden of opportunistic subclinical pathogens at the time of HAART introduction. Such a high burden of antigenic stimulation together with a dysregulated increased immune response during immunoreconstitution after HAART, may be responsible for the development of HIV-IRIS [90].

The immunopathogenic mechanisms associated with IRIS differ according to the type of pathogen involved [90]. CD8+ cytotoxic T cell response is associated with IRIS induced by viral infections [110,111] and a delayed type-hypersensitivity or a lymphoproliferative reaction with IRIS induced by mycobacterial infections [90,112,113].

### **IRIS associated HIV-KS**

Most HIV-seropositive subjects with KS do not demonstrate HHV-8-specific cytotoxic T lymphocyte response. This lack of HHV-8-specific cellular immune response during HIV infection is a contributory factor in the devel-

opment of HIV-KS. The decline in the incidence of HIV-KS, and the regression of KS in some HIV-seropositive subjects after the introduction of HAART, suggests that some general improvement in immunity and in the recovery of HHV-8-specific, MHC class I-restricted cytotoxic CD8+ T cell response could be important in the control of HHV-8 replication [114,115]. The CD4+ and CD8+ T cells that increase shortly after the introduction of HAART are memory cells. It is probable that in HIV-seropositive subjects who are commonly latently or subclinically coinfecting with HHV-8, the HHV-8-specific cytotoxic T cells lodge in sites of HHV-8 subclinical infection, or in sites of established KS lesions. In most of HIV-seropositive subjects, these CD8+ T cells will be protective and will control HHV-8 replication and spread, thus reducing the incidence of new KS lesions, and at times bringing about regression in established KS lesions. However in a minority of HIV-seropositive subjects with subclinical HHV-8 infection, or with established KS, such an immune response may be dysregulated and accompanied by an intensified HHV-8-specific inflammatory response paradoxically causing a worsening of KS and as a consequence, the development of IRIS-KS [112].

There could be other mechanisms that may be involved in the pathogenesis of IRIS-KS. As part of the immune restoration after HAART, there is a shift in the cytokine profile from the Th-2 to the Th-1 type. Th-1 cytokines have the capacity to reactivate latent HHV-8 in blood and tissue cells, and as a consequence, HHV-8 can spread to uninfected endothelial cells. Perhaps in a subset of HIV-seropositive subjects, the restored HHV-8-specific immune response following HAART is ineffective in controlling the increased HHV-8 antigens in blood and tissue cells, and as a result, paradoxically promotes the development of IRIS-KS.

Because of the inability of the immune response to control the HHV-8 infection, two processes may occur in parallel; the development of an exaggerated immunoinflammatory reaction characterized by the increased production of inflammatory cytokines in order to combat HHV-8; and secondly, the increase in the HHV-8 load in the tissues through autocrine and paracrine mechanisms increase the production of inflammatory cytokines, chemokines and growth factors. Together these processes upregulate the expression of  $\alpha\beta_3$  and  $\alpha_5\beta_1$ , and MMPs that induce the IRIS-KS angioproliferation and tumourigenesis [55]. In this context, HIV Tat protein and a profound state of immunosuppression do not significantly affect the development of IRIS-KS.

Bower et al. [33], reported that 10 of 150 (6.6%) HAART-naïve HIV-seropositive subjects with KS either developed new KS lesions or exhibited rapid progression of existing

KS lesions within 2 months of starting HAART. These subjects had a significantly higher CD4+ T cell count at the time of IRIS-KS diagnosis and a higher frequency of KS-associated oedema than HIV-seropositive subjects with KS who did not develop IRIS.

### Summary

The clinical course of HIV-KS is unpredictable. For some HIV-seropositive subjects, KS is a mild disease, while for others it may be rapidly progressive and aggressive. Regression of HIV-KS lesions and a substantial decrease in the incidence of HIV-KS occur after the introduction of HAART. However, a small subset of HIV-seropositive subjects with a low CD4 + T cell count at the time of HAART initiation, may develop IRIS associated HIV-KS shortly thereafter.

IRIS-KS is not a specific entity but it is a phenomenon which can be recognized by certain well defined circumstances: the presence of low CD4+ T cell counts at the time of introduction of HAART; a temporal relationship between rapid clinical progression of KS and the development of new KS lesions usually of about 8 weeks (though this period may range from 3 weeks to 22 weeks) after the initiation of HAART; and the suppression of HIV load and restoration of CD4+ T cell count.

### Competing interests

The author(s) declare that they have no competing interests.

### References

1. Leao JC, Caterino-de-Araujo A, Porter SR, Scully C: **Human herpesvirus 8 (HHV-8) and the etiopathogenesis of Kaposi's sarcoma.** *Rev Hosp Clin Fac Med Sao Paulo* 2002, **57**:175-186.
2. Tappero JW, Conant MA, Wolfe SF, Berger TG: **Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy.** *J Am Acad Dermatol* 1993, **28**:371-395.
3. Jensen KK, Manfra DJ, Grisotto MG, Martin AP, Vassileva G, Kelly K, et al.: **The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi's sarcoma.** *J Immunol* 2005, **174**:3686-3694.
4. Feller L, Jadwat Y, Raubenheimer EJ: **Kaposi sarcoma and calcium channel blocker-induced gingival enlargement occurring simultaneously: Review of the literature and report of a case.** *Oral Biosci Med* 2004, **4**:291-297.
5. Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM: **Profile of patients with Kaposi's Sarcoma in the era of highly active antiretroviral therapy.** *J Clin Oncol* 2005, **23**:1253-1260.
6. Fauci AS, Lane HC: **Human immunodeficiency virus disease: Aids and related disorders.** In *Harrison's Principles of Internal Medicine* 16th edition. Edited by: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. New York: McGraw-Hill; 2005:1076-1139.
7. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, et al.: **Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations and therapy.** *Lancet Infect Dis* 2002, **2**:281-292.
8. Flaitz CM, Jin YT, Hicks MJ, Nichols CM, Wang YW, Su JJ: **Kaposi's sarcoma associated herpesvirus-like DNA sequences (KSHV/HHV-8) in oral AIDS-Kaposi's sarcoma: a PCR and clinicopathologic study.** *Oral Surg Oral Med Oral Pathol Oral Radiol and Endod* 1997, **83**:259-264.
9. Von Roenn JH: **Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma.** *Hematol Oncol Clin North Am* 2003, **17**:747-762.
10. Monini P, Sgadari C, Barillari G, Ensoli B: **HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity.** *J Antimicrob Chemother* 2003, **51**:207-211.
11. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, et al.: **Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: Pathogenesis, Castleman's disease and pleural effusion lymphoma.** *Lancet Infect Dis* 2002, **2**:344-352.
12. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P: **Biology of Kaposi's sarcoma.** *Eur J Cancer* 2001, **37**:1251-69.
13. Krown SE: **Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms.** *Hematol Oncol Clin North Am* 2003, **17**:763-783.
14. Schwartz RA: **Kaposi's sarcoma: An update.** *J Surg Oncol* 2004, **87**:146-151.
15. Foreman KE, Friborg J, Chandran B, Katano H, Sata T, Mercader M, Nabel GJ, Nickoloff BJ: **Injection of human herpesvirus-8 in human skin engrafted on SCID induces Kaposi's sarcoma-like lesions.** *J Dermatol Sci* 2001, **26**:182-193.
16. Feller L, Lemmer J, Wood NH, Raubenheimer EJ: **Necrotizing gingivitis of Kaposi sarcoma affected gingivae.** *SADJ* 2006, **61**:314-317.
17. Moore PS, Chang Y: **Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection.** *N Engl J Med* 1995, **332**:1182-1185.
18. Huang YQ, Li JJ, Kaplan MH, Poiesz B, Katabira E, Zhang WC, et al.: **Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma.** *Lancet* 1995, **345**:759-761.
19. Forman KE, Bacon PE, Hsi ED, Nickoloff BJ: **In situ polymerase chain reaction-based localization studies support role of human herpes virus-8 as the cause of two AIDS-related neoplasms: Kaposi's sarcoma and body cavity lymphoma.** *J Clin Invest* 1997, **99**:2971-2978.
20. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, et al.: **Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression of Kaposi sarcoma.** *Lancet* 1995, **346**:799-802.
21. Moore PS, Kingsley LA, Holmberg SD, Spira T, Gupta P, Hoover DR, et al.: **Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma.** *AIDS* 1996, **10**:175-180.
22. Cattelan A, Calabro ML, Gasperini P, Aversa SM, Zanchetta M, Meneghetti F, et al.: **Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.** *J Natl Cancer Inst Monogr* 2001, **27**:44-49.
23. Bubman D, Cesarman E: **Pathogenesis of Kaposi's sarcoma.** *Hematol Oncol Clin North Am* 2003, **17**:717-745.
24. Engels EA, Biggar RJ, Marshall VA, Walters MA, Gamade CJ, Whitby D, et al.: **Detection and quantification of Kaposi's sarcoma associated herpes virus to predict AIDS-associated Kaposi's sarcoma.** *AIDS* 2003, **17**:1847-1851.
25. Simpson GR, Schultz TF, Whitby D, Cook PM, Boshoff C, Rainbow L, et al.: **Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant caspid protein and latent immunofluorescence antigen.** *Lancet* 1996, **348**:1133-1138.
26. Gao SJ, Kingsley L, Hoover DR, Spiro TJ, Rinaldo CR, Saah A, et al.: **Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.** *N Engl J Med* 1996, **335**:233-241.
27. Verbeek W, Frankel M, Miles S, et al.: **Seroprevalence of HHV-8 antibodies in HIV-positive homosexual men without Kaposi's sarcoma and their clinical follow-up.** *Am J Clin Pathol* 1998, **109**:778-783.
28. Mendez JC, Procop GW, Espy MJ, Paya CV, Smith TF: **Detection and semiquantitative analysis of human herpesvirus 8 DNA in specimens from patients with Kaposi's sarcoma.** *J Clin Microbiol* 1998, **36**:2220-2222.

29. Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R: **Classic Kaposi sarcoma: Epidemiology and risk factors.** *Cancer* 2000, **88**:500-517.
30. Connick E, Kane MA, White IE, Ryder J, Campbell TB: **Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy.** *Clin Infect Dis* 2004, **39**:1852-1855.
31. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F: **Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients.** *Nature* 1990, **345**:84-86.
32. Ensoli B, Gendelman R, Markham P, Fiorelli V, Columbini S, Raffeld M, et al.: **Synergy between basic fibroblast growth factor and the HIV-1 Tat protein in induction of Kaposi's sarcoma.** *Nature* 1994, **371**:674-680.
33. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, et al.: **Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma.** *J Clin Oncol* 2005, **23**:5224-5228.
34. Palella FJ Jr, Delaney KM, Marman AC, Loveless MO, Fuhreh J, Salten GA, et al.: **Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.** *N Engl J Med* 2003, **338**:853-860.
35. Portsmouth S, Stebbing J, Gazzard B: **Current treatment of HIV infection.** *Curr Top Med Chem* 2003, **3**:1458-1466.
36. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al.: **Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.** *Science* 1997, **277**:112-116.
37. Quinlivan EB, Zhang C, Stewart PW, Komoltri C, Davis MG, Wehbie RS: **Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not.** *J Infect Dis* 2002, **185**:1736-1744.
38. Jones JL, Hanson DL, Dworkin MS, Jaffe HW, et al.: **Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy.** *J Acquir Immune Defic Syndr* 2000, **24**:270-274.
39. Hermans P, Lundgren J, Sommereijns B, Katlama C, Chiesi A, Goebel FD, et al.: **Survival of European patients with Kaposi's sarcoma as AIDS-defining condition during the first decade of AIDS. AIDS in Europe study group.** *AIDS* 1997, **11**:525-531.
40. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, et al.: **A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.** *AIDS* 2003, **17**:F17-22.
41. Jacobson LP, Yamashita TE, Detels R, Margolick JB, Chmiel JS, Kingsley LA, et al.: **Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals.** *J Acquir Immun Defic Syndr* 1999, **21**:S34-41.
42. International Collaboration on HIV and Cancer: **Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.** *J Natl Cancer Institute* 2000, **92**:1823-1830.
43. Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, et al.: **Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.** *AIDS* 1998, **12**:F45-49.
44. Cattelan AM, Calabro ML, Aversa SM, Zanchetta M, Meneghetti F, De Rossi A, et al.: **Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.** *Eur J Cancer* 1999, **35**:1809-1815.
45. Aboulaia DM: **The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma.** *Chest* 2000, **117**:1128-1145.
46. Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R, et al.: **Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy.** *J Clin Oncol* 2001, **19**:3848-3851.
47. Pellet C, Chevret S, Blum L, Gauville C, Hurault M, Blanchard G, et al.: **Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.** *J Invest Dermatol* 2001, **117**:858-863.
48. Leitch H, Trudeau M, Routy JP: **Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy.** *HIV Clin Trials* 2003, **4**:107-114.
49. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B, et al.: **Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.** *AIDS* 1999, **13**:2105-2111.
50. Martinelli C, Zazzi M, Ambu S, Bartolozzi D, Corsi P, Leoncini F: **Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir.** *AIDS* 1998, **12**:1717-1719.
51. Pappas VA, Kyriakis KP, Papastamopoulos V, Hadjivassiliou M, Stavrinaes NG: **Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone.** *J Acquir Immune Defic Syndr* 2002, **30**:257-258.
52. Winceaslaus J: **Regression of AIDS-related pleural effusion with HAART: highly active antiretroviral therapy.** *Int J STD AIDS* 1998, **9**:368-370.
53. Boshoff C, Weiss R: **AIDS-related malignancies.** *Nat Rev Cancer* 2002, **2**:373-382.
54. Nasti G, Martellotta F, Beretta M, Menna M, Fasan M, Di Perri G, et al.: **Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi's sarcoma.** *Cancer* 2003, **98**:2440-2446.
55. Leidner RS, Aboulaia DM: **Recrudescence of Kaposi's sarcoma after initiation of HAART: A manifestation of immune reconstitution syndrome.** *Aids patient care STD* 2005, **19**:635-644.
56. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmor RL, Musher DW, et al.: **Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.** *Medicine* 2002, **81**:213-227.
57. Weir A, Wansbrough-Jones M: **Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient.** *AIDS* 1997, **11**:1895-1896.
58. Rizos E, Drosos AA, Ioannidis JP: **Isolated intraparotid Kaposi sarcoma in human immunodeficiency virus type 1 infection.** *Mayo Clin Proc* 2003, **78**:1561-1563.
59. Crane HM, Deubner H, Huang JC, Swanson PE, Harrington RD: **Fatal Kaposi's sarcoma-associated immune reconstitution following HAART initiation.** *Int J STD AIDS* 2005, **16**:80-83.
60. Mallery SR, Pei P, Kang J, Zhu G, Ness GM, Schwendeman SP: **Sustained angiogenesis enable in vivo transplantation of mucocutaneous derived AIDS-related Kaposi's sarcoma cells in murine hosts.** *Carcinogenesis* 2000, **21**:1647-1653.
61. Barillari G, Ensoli B: **Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma.** *Clin Microbiol Rev* 2002, **15**:310-326.
62. Sodhi A, Montaner S, Gutkind JS: **Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis?** *FASEB J* 2004, **18**:422-427.
63. Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, Sausville EA, et al.: **Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor.** *Proc Natl Acad Sci USA* 2004, **101**:4821-4826.
64. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, et al.: **The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1 alpha.** *Cancer Res* 2000, **60**:4873-4880.
65. Naranatt PP, Krishnan HH, Svojanovsky SR, Bloomer C, Mathur S, Chandran B: **Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection.** *Cancer Res* 2004, **64**:72-84.
66. Ensoli B, Sturzl M, Monini P: **Reactivation and role of HHV-8 in Kaposi's sarcoma initiation.** *Adv Cancer Res* 2001, **81**:161-200.
67. Buttiglieri S, Derigibus MC, Bravo S, Cassoni P, Chiarle R, Bussolati B, et al.: **Role of Pax 2 in apoptosis resistance and proinvasive**

- phenotype of Kaposi's sarcoma cells. *J Biol Chem* 2004, **279**:4136-4143.
68. Schwartz M, Murphy PM: **Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF- $\kappa$ B and induces proinflammatory cytokine and chemokine production via a c-terminal signaling determinant.** *J Immunol* 2001, **167**:505-513.
  69. Rabkin CS, Janz S, Lash A, Coleman AE, Musaba E, Liotta L, et al.: **Monoclonal origin of multicentric Kaposi's sarcoma lesions.** *N Engl J Med* 1997, **336**:988-993.
  70. Gill PS, Tsai YC, Rao AP, Spruck CH 3rd, Zheng T, Harrington WA Jr, et al.: **Evidence for multiclonality in multicentric Kaposi's sarcoma.** *Proc Natl Acad Sci USA* 1998, **95**:8257-8261.
  71. Mallory SR, Pei P, Landwehr DJ, Clark CM, Bradburn JE, Ness GM, et al.: **Implications for oxidative and nitrative stress in the pathogenesis of AIDS-related Kaposi's sarcoma.** *Carcinogenesis* 2004, **25**:597-603.
  72. Hynes RO: **Integrins: versatility, modulation and signaling in cell adhesion.** *Cell* 1992, **69**:11-25.
  73. Barillari G, Albonici L, Incerpi S, Bogetto L, Pistrutto G, Volpi A, et al.: **Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing  $\alpha$ 5 $\beta$ 1 integrin expression and function.** *Atherosclerosis* 2001, **154**:377-385.
  74. Toschi E, Barillari G, Sgadari C, Bacigalupo I, Cereseto A, Carlei D, et al.: **Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-I Tat protein and basic fibroblast growth factor.** *Mol Biol Cell* 2001, **12**:2934-2946.
  75. Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, Manzari V, et al.: **The Tat protein of human immunodeficiency virus type-I promotes vascular cell growth and locomotion by engaging the  $\alpha$ 5 $\beta$ 1 and  $\alpha$ v $\beta$ 3 integrins and by mobilizing sequestered basic fibroblast growth factor.** *Blood* 1999, **94**:663-672.
  76. Toschi E, Bacigalupo I, Strippoli R, Chiozzini C, Cereseto A, Falchi M, et al.: **HIV-I Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathways.** *Mol Biol Cell* 2006, **17**:1985-1994.
  77. Fanales Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A, et al.: **Native HIV-Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses.** *J Immunol* 2002, **168**:197-206.
  78. Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST: **Vascular endothelial growth factor increases release of gelatinase A and decrease release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro.** *Microvasc Res* 1998, **55**:29-42.
  79. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M: **T-lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor, and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells.** *Proc Natl Acad Sci USA* 1994, **91**:2890-2894.
  80. Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Morris CB, et al.: **Inflammatory cytokines synergize with HIV-I Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and  $\alpha$ v $\beta$ 3 integrin.** *J Immunol* 1999, **15**:1929-1935.
  81. Samaniego F, Markham PD, Gallo RC, Ensoli B: **Inflammatory cytokines induce AIDS-Kaposi's sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi's sarcoma-like lesion formation in nude mice.** *J Immunol* 1995, **154**:3582-3592.
  82. Bussolino F, Mitola S, Serini G, Barillari G, Ensoli B: **Interactions between endothelial cells and HIV-I.** *Int J Biochem Cell Biol* 2001, **33**:371-390.
  83. Ferrari N, Morini M, Pfeffer U, Minghelli S, Noonan DM, Albin A: **Inhibition of Kaposi's sarcoma in vivo by fenretinide.** *Clin Cancer Res* 2003, **9**:6020-6029.
  84. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al.: **Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin  $\alpha$ v $\beta$ 3.** *Cell* 1996, **85**:683-693.
  85. Seftor RE, Seftor EA, Stetler-Stevenson WG, Welch DR, Hendrix MJ: **The 72 kDa type IV collagenase is modulated via differential expression of  $\alpha$ v $\beta$ 3 and  $\alpha$ 5 $\beta$ 1 integrins during human melanoma cell invasion.** *Cancer Res* 1993, **53**:3411-3415.
  86. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB: **The multifaceted roles of nitric oxide in cancer.** *Carcinogenesis* 1998, **19**:711-721.
  87. Lucey DR, Clerici M, Shearer GM: **Type 1 and Type 2 cytokine dysregulation in human infectious, neoplastic and inflammatory diseases.** *Clin Microbiol Rev* 1996, **9**:532-562.
  88. Wilkinson J, Cope A, Gill J, Bourbouli D, Hayes P, Imami N, et al.: **Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific responses in human immunodeficiency virus type I-infected patients receiving highly active antiretroviral therapy.** *J Virol* 2002, **76**:2634-2640.
  89. Robertson P, Scadden DT: **Immune reconstitution in HIV infection and its relationship to cancer.** *Hematol Oncol Clin North Am* 2003, **17**:703-716.
  90. Cheng VCC, Yuen KY, Chan WM, Wong SSY, Ma ESK, Chan RMT: **Immuno-restitution disease involving the innate and adaptive response.** *Clin Infect Dis* 2000, **30**:882-892.
  91. Jubault V, Penforis A, Schillo F, Hoen B, Izembart M, Timsit J, et al.: **Sequential occurrence of thyroid autoantibodies and Grave's disease after immune restoration in severely immunocompromised human immunodeficiency virus-I infected patients.** *J Clin Endocrinol Metab* 2000, **85**:4254-4257.
  92. Lawn SD, Bekker LG, Miller RF: **Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.** *Lancet Infect Dis* 2005, **5**:361-373.
  93. Shelburne SA 3rd, Hamill RJ: **The immune reconstitution inflammatory syndrome.** *AIDS Rev* 2003, **5**:67-79.
  94. Shelburne SA, Visnegarwala F, Darcourt J, Graves EA, Giordano TP, White AC: **Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.** *AIDS* 2005, **19**:399-406.
  95. French MA, Lenzo N, John M, Mallai SA, McKinnin EJ, James IR, et al.: **Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy.** *HIV Med* 2000, **1**:107-115.
  96. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ: **Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type-I-infected cohort.** *Clin Infect Dis* 2006, **42**:418-427.
  97. Valdez H, Connick E, Smith KY, Leerman MM, Bosch RJ, Kim RS, et al.: **Limited immune restoration after 3 years' suppression of HIV-I replication in patients with moderately advanced disease.** *AIDS* 2002, **16**:1859-1866.
  98. Douek DC, McFarland RD, Keiser PH, Cagle FA, Massey JM, Haynes BF, et al.: **Changes in thymic function with age and during treatment of HIV infection.** *Nature* 1998, **396**:690-695.
  99. Zhang I, Lewin SR, Markowitz M, Linn HH, Skulski E, Karanickolas R, et al.: **Measuring recent thymic emigrants in blood of normal and HIV-I-infected individuals before and after effective therapy.** *J Exp Med* 1999, **190**:725-732.
  100. Carcelain G, Debre P, Autran B: **Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy.** *Curr Opin Immunol* 2001, **13**:483-488.
  101. Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Augut H, et al.: **Transient mobilization of human immunodeficiency virus (HIV) - specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type I infection.** *J Virol* 2001, **75**:234-241.
  102. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, et al.: **Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-I infection: a composite of redistribution and proliferation.** *Nat Med* 1998, **4**:208-214.
  103. Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, et al.: **Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.** *J Clin Invest* 1999, **103**:1391-1398.
  104. Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St Clair M, et al.: **Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.** *J Infect Dis* 2000, **181**:358-363.
  105. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, et al.: **Immunologic responses associated with 12 weeks combination antiretroviral therapy consisting of zido-**



- zidovudine, lamivudine and ritonavir: results of AIDS Clinical Trials Group Protocol 315.** *J Infect Dis* 1998, **178**:70-79.
106. Lederman MM: **Immune restoration and CD4+ T-cell function with antiretroviral therapies.** *AIDS* 2001, **15(Suppl 2)**:S11-15.
107. Jevtovic DJ, Salemovic D, Pesic I, Zerjav S, Djurkovic-Djakovic O: **The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy.** *HIV Med* 2005, **6**:140-143.
108. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ: **Immune reconstitution syndrome in HIV: Validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy.** *Clin Infect Dis* 2006, **42**:1639-1646.
109. Breton G, Duval X, Estellat C, Paoletti X, Bonnet D, Mvondo D, et al.: **Determinants of immune reconstitution inflammatory syndrome in HIV type-1-infected patients with tuberculosis after initiation of antiretroviral therapy.** *Clin Infect Dis* 2004, **39**:1709-1712.
110. Martinez E, Gatell J, Moran Y, Aznar E, Buira E, Guelar A, et al.: **High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors.** *Clin Infect Dis* 1998, **27**:1510-1513.
111. Domingo P, Torres OH, Ris J, Vazquez G: **Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection.** *Am J Med* 2001, **110**:605-609.
112. Foudraine NA, Hovenkamp E, Natermans DW, Meenhorst PL, Klein MR, Lange JMA, et al.: **Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients.** *AIDS* 1999, **13**:177-184.
113. French MAH, Malal SA, Dawkins RL: **Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients.** *AIDS* 1992, **6**:1293-1297.
114. Osman M, Kubo T, Gill J, Neipel F, Becker M, Smith G, et al.: **Identification of human herpesvirus 8-specific cytotoxic T-cell responses.** *J Virol* 1999, **73**:6136-6140.
115. Hirsh H, Kaufmann G, Sendi P, Battegay M: **Immune reconstitution in HIV-infected patients.** *Clin Infect Dis* 2004, **38**:1159-1166.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

